Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Exemestane & Breast Cancer / Mammacarcinoma (HR+) (ER+) (Her2-)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

Exemestane is approved by both the FDA and EMA for the treatment of Breast Cancer / Mammacarcinoma (HR+) (ER+) (Her2-), specifically in postmenopausal women. It is indicated as adjuvant therapy following tamoxifen treatment and for advanced or metastatic disease after progression on prior endocrine therapy (1, 2).

References:

(1) Kim & Lukong 2025 Oncol Rev 19: 1564642
(2) Walker et al. 2013 Patient Prefer Adherence 7: 245-58

…

References (Sources)

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
Bidard et al. 2022 J Clin Oncol 40(28): 3246-3256
Elacestrant Improves Progression-Free Survival After Endocrine Therapy for Estrogen Receptor-Positive Metastatic Breast Cancer
Jacobson 2022 Oncologist 27(Suppl 1): S7-S8
Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups
Bardia et al. 2024 Clin Cancer Res 30(19): 4299-4309
Long-term efficacy and safety of exemestane in the treatment of breast cancer
Walker et al. 2013 Patient Prefer Adherence 7: 245-58
Treating ER-positive breast cancer: a review of the current FDA-approved SERMs and SERDs and their mechanisms of action
Kim & Lukong 2025 Oncol Rev 19: 1564642
Review

AI Chat

7/1/2026

Chat with our artificial intelligence: